Ecallantide injection
Products billed under this code include Kalbitor.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Kalbitor.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Kalbitor | Takeda Pharmaceuticals America, Inc. | 47783-0101-01 | 30 | $17,988.48 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $599.616 | +$3.672 | 1 MG | Ecallantide injection | v1, posted September 17, 2026 |
| 3Q26 | $595.944 | +$17.197 | 1 MG | Ecallantide injection | v1, posted September 15, 2026 |
| 2Q26 | $578.747 | −$0.999 | 1 MG | Ecallantide injection | v1, posted September 15, 2026 |
| 1Q26 | $579.746 | −$0.219 | 1 MG | Ecallantide injection | v1, posted September 15, 2026 |
| 4Q25 | $579.965 | −$0.022 | 1 MG | Ecallantide injection | v1, posted September 8, 2026 |
| 3Q25 | $579.987 | +$15.346 | 1 MG | Ecallantide injection | v1, posted March 10, 2026 |
| 2Q25 | $564.641 | +$1.543 | 1 MG | Ecallantide injection | v1, posted March 10, 2026 |
| 1Q25 | $563.098 | −$2.728 | 1 MG | Ecallantide injection | v1, posted December 19, 2025 |
| 4Q24 | $565.826 | +$2.946 | 1 MG | Ecallantide injection | v1, posted June 11, 2025 |
| 3Q24 | $562.88 | +$17.263 | 1 MG | Ecallantide injection | v1, posted June 11, 2025 |
| 2Q24 | $545.617 | +$6.29 | 1 MG | Ecallantide injection | v1, posted March 11, 2025 |
| 1Q24 | $539.327 | +$7.082 | 1 MG | Ecallantide injection | v1, posted December 19, 2024 |
| 4Q23 | $532.245 | +$1.525 | 1 MG | Ecallantide injection | v1, posted October 10, 2024 |
| 3Q23 | $530.72 | +$10.223 | 1 MG | Ecallantide injection | v1, posted June 5, 2024 |
| 2Q23 | $520.497 | +$3.897 | 1 MG | Ecallantide injection | v1, posted February 23, 2024 |
| 1Q23 | $516.60 | −$3.626 | 1 MG | Ecallantide injection | v1, posted December 6, 2023 |
| 4Q22 | $520.226 | +$6.491 | 1 MG | Ecallantide injection | v1, posted June 22, 2023 |
| 3Q22 | $513.735 | +$12.375 | 1 MG | Ecallantide injection | v1, posted June 9, 2023 |
| 2Q22 | $501.36 | −$2.771 | 1 MG | Ecallantide injection | v1, posted December 14, 2022 |
| 1Q22 | $504.131 | +$0.253 | 1 MG | Ecallantide injection | v1, posted June 8, 2022 |
| 4Q21 | $503.878 | +$4.371 | 1 MG | Ecallantide injection | v1, posted June 2, 2022 |
| 3Q21 | $499.507 | +$7.063 | 1 MG | Ecallantide injection | v1, posted June 2, 2022 |
| 2Q21 | $492.444 | +$0.327 | 1 MG | Ecallantide injection | v1, posted March 1, 2022 |
| 1Q21 | $492.117 | – | 1 MG | Ecallantide injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.